LOW DOSAGE
STANOZOLOLUM TREATMENT IN CHILDREN WITH PARTIAL GROWTH HORMONE DEFICIENCY
Chen HS, Du ML, Ma HM, Li YH
Department of Pediatrics, The
First Affiliated Hospital, Sun Yat-sen University of Medical Sciences,
China
Objective: to analyze the efficacy
of stanozololum on the growth of the children with partial growth hormone
deficiency (PGHD).
Methods: Fourteen prepubertal
children with PGHD, 9 boys and 5 girls, aged from 3-12 years, were given
low dosage stanozololum (20-40ug/kg) treatment. After 6.54±2.56 (4-9)months treatment
period, the efficacy of the treatment was evaluated according to growth
velocity (GV), height z score for chronological age (HtSDSca), height z
score for bone age (HtSDSba),
the ratio of the increased height age/ the increased bone age(△HA/△BA), predicted adult height and
IGF-I.
Results: The GV of the patients
increased from （4.18±1.25 ） cm/a to （8.72±2.54） cm/a （p=0）. HtSDSca increased from (-2.58±0.55) to (-2.36±0.6) （p=0.001）; HtSDSba increased from (-1.17±0.58) to (-0.91±0.65) （p<0.05）. Mean △HA/△BA was （1.91±1.67）; of the 14 children , the △HA/△BA<1 in 4 individuals and
>1 in the other 10. Predicted adult height increases from （156.2±4.76） cm to （158.08 ±6.59） cm （p<0.05）. IGF-I level increased from （286.54±142.21） ng/ml to (534±198.95) ng/ml (p<0.01). Z
score of IGF-I increased from （-0.48±0.74） to （0.87±0.82） (p<0.01).
Conclusion:
Short-term treatment of low dosage stanozololum facilitates the growth of
prepubertal children with PGHD. We presume that it affects the growth by
increasing the IGF-I secretion of the patients. It is necessary to observe
the bone age carefully because the acceleration in bone maturation is more
than the height gain in some individuals.